Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Trastuzumab Regimens in HER2+ Breast Cancer (BCIRG-006)
NCT00021255Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2001
- Primary completion
- Dec 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 42
01
Overview
Phase 3, randomised, open-label trial of trastuzumab in breast cancer (3 arms), sponsored by Sanofi. Primary endpoint: Disease Free Survival at 5 years. Started Apr 2001; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00021255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00021255.